Cargando…
Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?
Chronic Myeloid Leukemia (CML) is a rare malignant proliferative disease of the hematopoietic system, whose molecular hallmark is the Philadelphia chromosome (Ph). The Ph chromosome originates an aberrant fusion gene with abnormal kinase activity, leading to the buildup of reactive oxygen species an...
Autores principales: | Abdulmawjood, Bilal, Costa, Beatriz, Roma-Rodrigues, Catarina, Baptista, Pedro V., Fernandes, Alexandra R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626020/ https://www.ncbi.nlm.nih.gov/pubmed/34830398 http://dx.doi.org/10.3390/ijms222212516 |
Ejemplares similares
-
Liquid biopsies in myeloid malignancies
por: Abdulmawjood, Bilal, et al.
Publicado: (2019) -
Editorial: Cancer Nanotheranostics: What Have We Learned So Far?
por: Conde, João, et al.
Publicado: (2016) -
Ovarian Cancer Radiosensitivity: What Have We Understood So Far?
por: Barcellini, Amelia, et al.
Publicado: (2022) -
COVID-19: What We Have Learned So Far
por: Clifford, Theresa
Publicado: (2020) -
Pediatric Myocarditis: What Have We Learnt So Far?
por: Pomiato, Elettra, et al.
Publicado: (2022)